Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...
The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...
Hosted on MSN1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call TranscriptThis strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
(Schnirring, 11/12) Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug application for its COVID-flu combination and standalone flu ...
Yes, you can get your flu and COVID-19 shots at the same time. Don’t call them boosters — they’re not just another dose of ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Biotech firm Novavax dropped after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...
This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback